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Abstract
Analgesic and sedative medications are widely used in intensive
care units to achieve patient comfort and tolerance of the intensive
care unit environment, and to eliminate pain, anxiety, delirium and
other forms of distress. Surveys and prospective cohort studies
have revealed wide variability in medication selection, monitoring
using sedation scales, and implementation of structured treatment
algorithms among practitioners in different countries and regions of
the world. Successful management of analgesia and sedation
incorporates a patient-based approach that includes detection and
management of predisposing and causative factors, including
delirium; monitoring using analgesia and sedation scales and other
instruments; proper medication selection, with an emphasis on
analgesia-based drugs; and incorporation of structured strategies
that have been demonstrated to reduce likelihood of excessive or
prolonged sedation.
All clinicians who provide care to critically ill patients face
many daily management challenges, including ensuring patient
comfort and tolerance of the intensive care unit (ICU)
environment, while avoiding complications related to therapy.
This seemingly straightforward task of safely maintaining
patient comfort in fact requires an appreciation of the many
factors that may influence the patient’s state of comfort or
distress and the inter-relationship with ICU-related processes.
Pain is the root cause of distress experienced by many ICU
patients [1-4], but anxiety, dyspnea, delirium, sleep
deprivation, and other factors can contribute and are often
additive or synergistic [5-8]. The predisposing and causative
conditions that provoke these components of distress range
widely, and include underlying medical conditions (such as
arthritis or chronic pain syndrome) and acute medical or
surgical illness, as well as many ‘routine’ aspects of critical
care such as mechanical ventilation, indwelling tubes and
catheters, iatrogenic illness, medication side effects, nursing
interventions such as turning and suctioning, and excessive
ICU noise and light [9]. Thus, improving the patient’s
tolerance of these common issues that contribute to a state
of relative discomfort or outright distress is important [9-13].
Analgesia and sedation management has routinely been
employed in ICU patients for many years, particularly among
those receiving mechanical ventilation [14]. Surveys of ICU
practitioners indicate continued widespread use and provide
insight into the diversity of approaches, including the relative
frequency with which specific medications are utilized and
variability in monitoring, protocol use, and other clinical
practice parameters [15-25]. An international cohort study of
mechanically ventilated adults conducted in 1998 [26] (48%
from Europe, 24% from Latin America, and 28% from North
America) provides an instructive global composite of clinical
practice. Only 68% of patients received an analgesic or
sedative drug at some time during mechanical ventilation,
with a median of 3 days of use. At least one analgesic or
sedative drug was used on 58% of days of ventilatory
support, including benzodiazepines in 69%, propofol in 21%,
and opioids in 63% of sedation days. Heterogeneity in clinical
practice for different regions of the world was demonstrated,
with use of analgesic and sedative drugs being most
common in Europe and least common in Latin America.
Soliman and colleagues [19] found considerable variability
among European countries regarding use of sedatives
(midazolam and propofol were used most widely) and
analgesic medications (morphine and fentanyl were most
often utilized). A recent observational study conducted in 44
ICUs in France [25] indicates slightly greater use of opioids
(90%) as compared with sedatives (72%), a transition to
sufentanil and fentanyl as preferred analgesics, and
continued under-use of monitoring, with only about 40%
receiving sedation or analgesia assessments.
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The use of a sedation scale and sedation guidelines also
varies widely among countries [19]. Surveys and observa-
tional studies indicate that no more than one-half of
practitioners, when queried during the late 1990s through to
2004, reported routine use of a sedation scale [16,19-25].
Whether these published findings accurately reflect current
practice in 2008 is speculative, however, because the most
recently reported survey period is 2004 [25]. It is likely that
the publication of the Society of Critical Care Medicine’s
clinical practice guidelines for the management of sedation
and analgesia [27], as well as clinical trials that reported
improved outcomes with algorithm-based approaches to
sedation management [28-32], have raised clinician aware-
ness and led to more structured management.
The contents of this supplement to Critical Care highlight key
principles and new developments in the management of
analgesia and sedation in the ICU setting. Successful
management of patient comfort and tolerance of the ICU
environment incorporates recognition and management of
predisposing and causative factors, use of nonpharmacologic
measures to reduce discomfort and distress, and use of
analgesic and sedative medications to control pain and
anxiety. Although pain and anxiety are widely recognized as
important underlying conditions and targets for therapy, there
is increasing evidence that delirium is common and
associated with worse outcomes in mechanically ventilated
ICU patients [33]. In their review (included in this supple-
ment), Girard and coworkers [34] address basic concepts of
as well as novel approaches to detection and management of
delirium. An important component of addressing causative
factors such as pain, as well as assessing the response to
therapy and avoidance of over-sedation, is a structured
approach to monitoring [35]. The available tools, rationale,
and use of pain assessment tools, sedation scales, agitation
scales, and technology-based brain monitoring are reviewed
as part of this supplement by Sessler and colleagues [36].
It is important to keep in mind the considerable variability
among patients with respect to the most important issues and
optimal choices in pharmacologic management, based on such
factors as age and organ dysfunction. There is emerging
evidence that genetic variability exists for relative susceptibility
to opioids [37] and probably for other important drug classes
[38]. In addition, the patient’s condition typically changes over
the course of ICU hospitalization, as do the targets for
analgesia and sedation. For example, although low-tidal volume
ventilation is not associated with increased sedation needs
[39], use of unique ventilatory strategies such as high
frequency oscillatory ventilation may require deep sedation until
improvement occurs [40]. Thus, utilizing a patient-focused
approach to analgesia and sedation with frequent re-evaluation
and adjustment is important to achieving optimal outcomes.
The final three papers included in this supplement address
various aspects of comprehensive analgesia and sedation
management. Gommers and Bakker [41] provide a
comprehensive review of the analgesic and sedative drugs
that are currently utilized, comparing pharmacologic
characteristics as well as advances in the use of individual
agents and their limitations.
Although it is well accepted that analgesics play a central role
in modern analgesia and sedation concepts [32,42],
continuous infusions of conventional opioids can lead to
accumulation and prolonged drug effects, thereby potentially
increasing the time on the ventilator, the length of ICU stay,
and the probability of acquiring ventilator-associated pneu-
monia [43]. Remifentanil, a short-acting opioid that is
metabolized by unspecific blood and tissue esterases
independent of the duration of infusion or organ insufficiency,
was shown in recent clinical research to have a rapid and
predictable offset of effect, potentially allowing for a reduction
in weaning and extubation times and better differentiation
between over-sedation and brain dysfunction [44]. Wilhelm
and Kreuer [45], in this supplement, provide an overview of
the role of short-acting opioids in ICU analgesia and sedation.
Other major advances in analgesia and sedation manage-
ment have been achieved through optimizing the use of
newer and older medications through novel treatment
strategies, which have been demonstrated in prospective
trials to improve outcomes such as duration of mechanical
ventilation. Several key concepts underlie these strategies.
Many newer approaches emphasize titrating medications to
achieve targets while avoiding over-sedation [46]. Others
focus on providing defined periods during which medications
are discontinued in order to achieve a period of relative
alertness, thus reducing the likelihood of drug accumulation
and providing additional opportunities for ventilator weaning
[28,29,31]. It is now appreciated that the interplay between
various underlying factors is important for effective manage-
ment. This recognition has led to comprehensive approaches
that emphasize structured detection and quantification of pain,
agitation and patient-ventilator interactions, and measurement
of the depth of sedation [1,30]. In their review (included in this
supplement), Schweikert and Kress [47] address important
published analgesia and sedation management algorithms,
with particular emphasis on daily interruption of sedation as an
effective tool for avoiding excessive sedation.
Although considerable attention is given to initiation and
maintenance of effective sedative therapy, de-escalation and
discontinuation of therapy is an area of increasing focus.
There is a need to consider alternatives to parenteral therapy,
such as enteral therapy [48], for long-term or de-escalation of
therapy. Withdrawal syndromes from opioids and sedatives
may occur during the recovery phase of critical care illness
[49], but the prevalence and timing of their development are
unclear [50]. Finally, the long-term effects of analgesic and
sedative drug management on neuropsychological function
remain to be defined [51-53].Page 3 of 4
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It is clear that analgesic and sedative drug therapy in ICU
patients is evolving rapidly, with newer medications and novel
management strategies. The goals of providing patient
comfort and tolerance of the ICU environment while avoiding
excessive or prolonged sedation remain central to supportive
care of the critically ill patient. Effective, structured approaches
to sedation can pay important dividends, such as more
precise control of analgesia and sedation, shorter time on
mechanical ventilation, fewer complications, and faster
discharge from the ICU. Many challenges remain that will be
addressed by future research and innovative thinking.
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